Caligan Partners’s ADMA Biologics ADMA Stock Holding History

Caligan Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.9M	Buy	5,725,007 +968,496	+20%	+$8.83M	2.25%	9
2026 Q1	$42.9M	Buy	4,756,511 +1,744,003	+58%	+$27.5M	2.85%	12
2025 Q4	$54.9M	Buy	3,012,508 +375,899	+14%	+$6.34M	4.52%	8
2025 Q3	$38.7M	Buy	+2,636,609	New	+$45.2M	5.06%	8
2024 Q1	–	Sell	-473,087	Closed	-$2.14M	–	13
2023 Q4	$2.14M	Sell	473,087 -124,426	-21%	-$460K	0.72%	10
2023 Q3	$2.14M	Sell	597,513 -250,000	-29%	-$962K	0.98%	9
2023 Q2	$3.13M	Sell	847,513 -815,100	-49%	-$3.02M	1.76%	9
2023 Q1	$5.5M	Sell	1,662,613 -1,013,480	-38%	-$3.5M	3.84%	6
2022 Q4	$10.4M	Buy	+2,676,093	New	+$8.25M	8.64%	4

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caligan Partners's ADMA Position: Q2 2026 in Review

Caligan Partners increased its ADMA Biologics (ADMA) stake by 20% in Q2 2026, buying an estimated $8.83M and bringing the position to 5,725,007 shares worth $47.9M. The position accounts for 2.25% of the portfolio, ranked #9.

Caligan Partners first reported a position in ADMA in Q4 2022 and has held it in 9 quarters since. The position peaked at $54.9M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Caligan Partners held 5,725,007 shares of ADMA Biologics worth $47.9M as of Q2 2026.
Caligan Partners bought 968,496 ADMA Biologics shares in Q2 2026, an estimated $8.83M.
ADMA Biologics made up 2.25% of Caligan Partners's portfolio in Q2 2026, its #9 holding.
Caligan Partners first reported a position in ADMA Biologics in Q4 2022 and has held it in 9 quarters since.
Caligan Partners's ADMA Biologics position peaked at $54.9M in Q4 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.